Targeting Bladder Tumor Cells In vivo and in the Urine with a Peptide Identified by Phage Display
暂无分享,去创建一个
Erkki Ruoslahti | Byung-Heon Lee | E. Ruoslahti | In‐San Kim | Je-Yong Choi | T. Kwon | R. Park | Seung-min Lee | Je-Yong Choi | Rang-Woon Park | H. Hong | E. Yoo | Seung-Min Lee | Tae-Hwan Kwon | In-San Kim | Hai-Yan Hong | Eun-Ju Lee | Mi-Kyung Kwon | Tae-Gyun Kwon | Eun-Sang Yoo | Gil-Suk Yoon | T. Kwon | Eun-Ju Lee | Mi-Kyung Kwon | Byungheon Lee | Gil-Suk Yoon
[1] Han-Chung Wu,et al. A Novel Peptide Specifically Binding to Nasopharyngeal Carcinoma For Targeted Drug Delivery , 2004, Cancer Research.
[2] M. Marberger,et al. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? , 1998, The Journal of urology.
[3] C. Ohyama,et al. Endoscopic observation for detection and monitoring ofN-butyl-N-(4-hydroxybutyl)nitrosamine — induced bladder tumor in rats , 2004, Urological Research.
[4] R. Juliano,et al. Integrin Signaling , 2005, Cancer and Metastasis Reviews.
[5] Marije Deutekom,et al. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. , 2003, The Journal of urology.
[6] Erkki Ruoslahti,et al. αv Integrins as receptors for tumor targeting by circulating ligands , 1997, Nature Biotechnology.
[7] Y. Kim,et al. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. , 1989, Cancer research.
[8] Timo Sorsa,et al. Tumor targeting with a selective gelatinase inhibitor , 1999, Nature Biotechnology.
[9] Ralph Weissleder,et al. Detection of Invasive Colon Cancer Using a Novel, Targeted, Library-Derived Fluorescent Peptide , 2004, Cancer Research.
[10] T. Carey,et al. Loss of co-localization of alpha 6 beta 4 integrin and collagen VII in bladder cancer. , 1994, The American journal of pathology.
[11] R. Jain. The next frontier of molecular medicine: Delivery of therapeutics , 1998, Nature Medicine.
[12] R. Millikan,et al. Focus on bladder cancer. , 2004, Cancer cell.
[13] J. Schalken,et al. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. , 1993, Cancer research.
[14] Erkki Ruoslahti,et al. Anti-cancer activity of targeted pro-apoptotic peptides , 1999, Nature Medicine.
[15] C. Parsons,et al. Bladder-surface glycosaminoglycans: an efficient mechanism of environmental adaptation. , 1986, Science.
[16] M. Marberger,et al. Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. , 1999, The Journal of urology.
[17] P. Bannasch,et al. Expression of MUC1, Thomsen-Friedenreich antigen, Tn, sialosyl-Tn, and α2,6-linked sialic acid in hepatocellular carcinomas and preneoplastic hepatocellular lesions , 1999, Virchows Archiv.
[18] G. Clayman,et al. Isolation of a peptide for targeted drug delivery into human head and neck solid tumors. , 2000, Cancer research.
[19] J. Richie,et al. Biology and management of bladder cancer. , 1990, The New England journal of medicine.
[20] J. Folkman. What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.
[21] B. Bernard,et al. Anticancer activity of targeted proapoptotic peptides. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[22] C. Wood,et al. Targeting urothelium: ex vivo assay standardization and selection of internalizing ligands. , 2003, The Journal of urology.
[23] A. Harris,et al. The epidermal growth factor receptor and the prognosis of bladder cancer , 1990, Cancer.
[24] G. P. Smith,et al. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. , 1985, Science.
[25] J. Robinson. The lower urinary tract. , 1982, British journal of clinical pharmacology.
[26] D. Hanahan,et al. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. , 2003, Cancer cell.
[27] R. Ladner,et al. Phage display-derived peptides as therapeutic alternatives to antibodies. , 2004, Drug discovery today.
[28] T. Sun,et al. Uroplakins, specific membrane proteins of urothelial umbrella cells, as histological markers of metastatic transitional cell carcinomas. , 1995, The American journal of pathology.
[29] E. Ruoslahti,et al. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.
[30] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[31] K. Gish,et al. OB-BP1/Siglec-6 , 1999, The Journal of Biological Chemistry.
[32] Erkki Ruoslahti,et al. Organ targeting In vivo using phage display peptide libraries , 1996, Nature.
[33] A. Böhle,et al. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. , 2003, The Journal of urology.